The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
Open accessAbstract
Background Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor, has been proposed to mitigate the cytokine storm syndrome associated with severe COVID-19. We aimed to investigate the association between tocilizumab exposure and hospital-related mortality among patients requiring intensive care unit (ICU) support for COVID-19. Methods We did a retrospective observational cohort study at 13 hospitals within the Hackensack Meridian Health network (NJ, USA). We included patients (aged ≥18 years) with laboratory-confirmed COVID-19 who needed support in the ICU. We obtained data from a prospective observational database and compared outcomes in patients who received tocilizumab with those who did not. We applied a multivariable Cox model with propensity score matching to reduce confounding effects. The primary endpoint was hospital-related mortality. The prospective observational database is registered on ClinicalTrials.gov, NCT04347993. Findings Between March 1 and April 22, 2020, 764 patients with COVID-19 required support in the ICU, of whom 210 (27%) received tocilizumab. Factors associated with receiving tocilizumab were patients' age, gender, renal function, and treatment location. 630 patients were included in the propensity score-matched population, of whom 210 received tocilizumab and 420 did not receive tocilizumab. 358 (57%) of 630 patients died, 102 (49%) who received tocilizumab and 256 (61%) who did not receive tocilizumab. Overall median survival from time of admission was not reached (95% CI 23 days–not reached) among patients receiving tocilizumab and was 19 days (16–26) for those who did not receive tocilizumab (hazard ratio [HR] 0·71, 95% CI 0·56–0·89; p=0·0027). In the primary multivariable Cox regression analysis with propensity matching, an association was noted between receiving tocilizumab and decreased hospital-related mortality (HR 0·64, 95% CI 0·47–0·87; p=0·0040). Similar associations with tocilizumab were noted among subgroups requiring mechanical ventilatory support and with baseline C-reactive protein of 15 mg/dL or higher. Interpretation In this observational study, patients with COVID-19 requiring ICU support who received tocilizumab had reduced mortality. Results of ongoing randomised controlled trials are awaited. Funding None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · doi:10.1101/2020.06.22.20137273 · Cited by 11,475
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Matching Methods for Causal Inference: A Review and a Look Forward
Stuart, E. A. (2010) · Statistical Science · doi:10.1214/09-sts313 · Cited by 5,478
Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference
Ho, D. E., Imai, K., King, G., & Stuart, E. A. (2007) · Political Analysis · doi:10.1093/pan/mpl013 · Cited by 4,205
Effective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
Channappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524
Real-World Evidence — What Is It and What Can It Tell Us?
Sherman, R. E., Anderson, S. A., Dal Pan, G. J., Gray, G. W., Gross, T., Hunter, N. L., LaVange, L., Marinac-Dabic, D., Marks, P. W., Robb, M. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmsb1609216 · Cited by 2,063
Zhang, C., Wu, Z., Li, J.-W., Zhao, H., & Wang, G.-Q. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105954 · Cited by 1,758
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102537 · Cited by 1,654
Cited by
COVID-19-associated coagulopathy and disseminated intravascular coagulation
Asakura, H., & Ogawa, H. (2021) · International Journal of Hematology · doi:10.1007/s12185-020-03029-y · Cited by 442
Bienvenu, L. A., Noonan, J., Wang, X., & Peter, K. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa284 · Cited by 338
Sinha, P., Furfaro, D., Cummings, M. J., Abrams, D., Delucchi, K., Maddali, M. V., He, J., Thompson, A., Murn, M., Fountain, J., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202105-1302oc · Cited by 286
Interleukin-6: obstacles to targeting a complex cytokine in critical illness
McElvaney, O. J., Curley, G. F., Rose-John, S., & McElvaney, N. G. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00103-x · Cited by 278
Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection
Desai, N., Neyaz, A., Szabolcs, A., Shih, A. R., Chen, J. H., Thapar, V., Nieman, L. T., Solovyov, A., Mehta, A., Lieb, D. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20139-7 · Cited by 245
Metadata
- Authors
- Biran, N., Ip, A., Ahn, J., Go, R. C., Wang, S., Mathura, S., Sinclaire, B. A., Bednarz, U., Marafelias, M., Hansen, E., Siegel, D. S., Goy, A. H., Pecora, A. L., Sawczuk, I. S., Koniaris, L. S., Simwenyi, M., Varga, D. W., Tank, L. K., Stein, A. A., Allusson, V., Lin, G. S., Oser, W. F., Tuma, R. A., Reichman, J., Brusco, L., Carpenter, K. L., Costanzo, E. J., Vivona, V., & Goldberg, S. L.
- Venue
- The Lancet Rheumatology
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 2
- Issue
- 10
- Pages
- e603-e612
- ISSN
- 2665-9913 (ISSN-L)
- OpenAlex
- W3048601848
- Cited by
- 275
- References
- 26
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. https://app.cochat.ai/papers/10.1016/s2665-9913(20)30277-0
- The paper
- Biran, N., Ip, A., Ahn, J., Go, R. C., Wang, S., Mathura, S., Sinclaire, B. A., Bednarz, U., Marafelias, M., Hansen, E., Siegel, D. S., Goy, A. H., Pecora, A. L., Sawczuk, I. S., Koniaris, L. S., Simwenyi, M., Varga, D. W., Tank, L. K., Stein, A. A., . . . Goldberg, S. L. (2020). Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. The Lancet Rheumatology. https://doi.org/10.1016/s2665-9913(20)30277-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.